⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory marginal zone lymphoma

Every month we try and update this database with for refractory marginal zone lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesNCT04205409
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Recurrent Plasm...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Plas...
Recurrent Mantl...
Refractory Mant...
Nivolumab
18 Years - University of Washington
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaNCT03479268
B-Cell Prolymph...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Pevonedistat
Pharmacokinetic...
Pharmacological...
18 Years - City of Hope Medical Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaNCT04635683
Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589
Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589
Relapsed Non-Ho...
Refractory Non-...
Relapsed Chroni...
Refractory Chro...
Relapsed Follic...
Relapsed Margin...
Relapse Diffuse...
Relapsed Small ...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Richter Transfo...
Refractory Diff...
Transformed Non...
BGB-21447
18 Years - BeiGene
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaNCT04635683
Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaNCT02568553
Recurrent Burki...
Recurrent Diffu...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Gray-...
Recurrent Mantl...
Recurrent Margi...
Recurrent Media...
Recurrent Non-H...
Recurrent Small...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Gray...
Refractory Mant...
Refractory Marg...
Refractory Medi...
Refractory Non-...
Refractory Smal...
Blinatumomab
Lenalidomide
18 Years - National Cancer Institute (NCI)
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNCT01955499
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Computed Tomogr...
Ibrutinib
Lenalidomide
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaNCT01995669
Grade 3a Follic...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Foll...
Refractory Marg...
Refractory Smal...
Laboratory Biom...
Lenalidomide
Obinutuzumab
18 Years - M.D. Anderson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaNCT03583424
Hematopoietic C...
Recurrent Diffu...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Tran...
Carmustine
Cytarabine
Etoposide
Hematopoietic C...
Melphalan
Venetoclax
19 Years - Ohio State University Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone LymphomaNCT06300528
Recurrent Extra...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Refractory Extr...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Computed Tomogr...
Pemigatinib
Positron Emissi...
18 Years - Ohio State University Comprehensive Cancer Center
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaNCT05025800
Aggressive B-Ce...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Composite Lymph...
Indolent B-Cell...
Refractory Aggr...
Refractory Foll...
Refractory Grad...
Refractory High...
Refractory Mant...
Refractory Marg...
Refractory Prim...
Refractory Tran...
Refractory Tran...
Richter Syndrom...
CD47 Antagonist...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04659044
Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaNCT04578600
Indolent B-Cell...
Recurrent B-Cel...
Recurrent Chron...
Recurrent Mucos...
Recurrent Folli...
Recurrent Hairy...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Chro...
Refractory Muco...
Refractory Foll...
Refractory Hair...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Recurrent Small...
Refractory Smal...
Lenalidomide
Obinutuzumab
Oral Azacitidin...
18 Years - University of California, Davis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: